

Polymer Factory Sweden AB (publ) Interim Report Q2 2021

The period in summary

Second quarter, April-June 2021

- The company was listed on Spotlight Stock Market with first day of trading 7th April 2021.
- A new CEO started 1st April 2021.
- The loss for the period amounted to KSEK -922, of which KSEK 200 can be derived from IPO related activities.
- Net sales for the period increased with 177% Q2.

Year to date, January-June 2021

- The operating loss for the period amounted to KSEK -1,414, of which KSEK 691 can be derived from IPO related activities.
- Net sales for the period increased with 121% for year-to-date.

Key Figures

(KSEK)	Apr-Jun 2021	Apr-Jun 2020	Jan-Jun 2021	Jan-Jun 2020
Net sales	643	232	1,427	654
Operating profit	-922	-253	-1,414	-346
Cash flow for the period	9,063	42	9,725	396
Profit (loss) for the period	-922	-254	-1,599	-348
Basic earnings per share (SEK)	-0.13	-0.25*	-0.23	-0.35*

*Share volume 2020 is adjusted for a split 1:1000

Comments from CEO Elin Mignérus

During Q2 2021, Polymer Factory has seen big changes; a new CEO has entered and on April 7th the Company had its first day of trading at Spotlight Stock Market. After landing in the new position as a public company, we are now fully focused on scaling up the activities to realize the Company's full potential.

We have now closed our first quarter as a listed company and after an intense start of the quarter with the IPO, me taking place as the new CEO and starting our communication with the market, we have been able to focus on our business and company development activities. During this second quarter of 2021, we have already achieved several of the goals set out for the year – something that we are proud of, but will not stop at.

During the period, we have gladly seen several new and returning customers, increasing the net sales for the period with 177% compared to the second quarter 2020, landing at KSEK 643 (232). Operating result amounted to KSEK -922 (-254) for the second quarter, accumulating to a total of KSEK -1,414 (-346) for the first half of the year. Sales have been distributed across a range of customers, sectors and products, but we have also seen a larger single order of approximately KSEK 200 from our Hyperbranched materials segment.

A lot of focus has been put into strengthening the company and investing for growth, and in line with this we have been happy to announce the recruitment of two new employees; with this strengthened organization, we will have more manpower to scale the business activities further. Furthermore, we also announced the signing of new lab space and investment in a MALDI-TOF-MS instrument for use in the analytical materials segment. Moving forward, this means that we

can focus even more on the growth of our SpheriCal® platform and the launch of the Dendritic Nano Gels (DNG) segment, to realize the potential of our entire platform.

We see great interest from and potential in companies of different sizes and from several sectors, where biotechnology has been standing out during Q2. Through the contact with our current and future customers, the diversity of our product portfolio and its potential use cases truly shines through - applications range from internal calibration, vaccines, and pharma to coating.

Now putting the summer behind us, we at Polymer Factory are eager to take on the rest of the year with several exciting things to come. Growing our business permeates all activities at Polymer Factory, and we will continue setting high goals and work to achieve them all!

About Polymer Factory

Polymer Factory was founded in 2006 at KTH Royal Institute of Technology and its Board of Directors have been essential in driving dendritic nanotechnology research to commercialization for almost 15 years – expertise that has been transferred to the Company's products. Emerging from many years of cutting-edge research within the field, Polymer Factory today has, in the Company's assessment, the world's largest product portfolio of dendritic materials with customers ranging from Big Pharma, MedTech and BioTech companies, to research-intensive institutes and academic research groups. Polymer Factory has also used the Company's vast knowledge and expertise to develop a patented calibration technology, named SpheriCal®, designed for Mass Spectrometry instruments.

For more information, please contact:

Elin Mignérus, CEO

Phone: +46 (0) 79 300 27 76

E-mail: elin.mignerus@polymerfactory.com

This disclosure contains information that Polymer Factory is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 25 August 2021.

Polymer Factory (publ) is a leading global provider and producer of dendritic materials, with customers ranging from Big Pharma, MedTech and BioTech companies, to research-intensive institutes and academic research groups. The Company's dendritic materials act as smart delivery systems that enhance the effects of the substances they carry, e.g., a vaccine or an anticancer drug. They have also shown great promise in diagnostics, tissue engineering and in the development of vaccines. In addition, Polymer Factory has used the Company's vast knowledge and expertise to develop a patented calibration technology, named SpheriCal®, designed for Mass Spectrometry instruments. The Company's dendritic nanotechnologies have the potential to accelerate innovation in technologically demanding sectors, such as MedTech and BioTech. Learn more at www.polymerfactory.com.